AlphAIAlphAI — Financial news for AI agents
tradingview.comOCT 301 min read$LLY

JP Morgan maintains Eli Lilly at Overweight, raises price target to $1650 from $1500

JP Morgan kept its Overweight rating on Eli Lilly (LLY) but raised its price target to $1650 from $1500, citing a 16.4% upside from the Oct 30 close. Recent analyst targets for LLY range from $1500 to $1650.

Original reporting
tradingview.com
Published Oct 30, 2026, 10:13 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 30, 2026, 10:19 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
JP Morgan maintains Eli Lilly at Overweight, raises price target to $1650 from $1500 — source image
Source · tradingview.com
Decision brief

The 30-second read

$LLYBullishMed
01

Why it matters

The price target increase signals confidence but lacks fresh operational data, so impact may be modest.

02

Market read

Analyst target raise provides a modest bullish cue for LLY and potentially the broader pharma sector.

03

What to watch

No new earnings or product data accompany the upgrade.

Relevance 7/10Novelty 6/10Timing: after-hours

Background

Eli Lilly (LLY) is a large-cap pharmaceutical company; analyst upgrades can influence short-term price action.

Company-level read

Ticker impact

$LLYBullishHigh confidence
Context

JP Morgan raised its price target on Eli Lilly to $1650 from $1500, indicating a bullish outlook.

Expected impact

likely upward pressure as investors price in the higher target

Evidence & confidence

Target raise reflects improved expectations and may attract buying interest.

Market effects

Sector

May lift sentiment for the pharma sector.

Regional

U.S. biotech stocks could see modest gains.

Global

Limited to investors tracking large-cap pharma.

Counterpoint

What could challenge this read

Target raises can be premature; price may already reflect expectations.

Key entities

  • Analyst
    JP Morgan

    Equity research firm raising LLY price target.

Read at source← All news

Related articles

OCT 30
$LLYMedAI 8/10

What Eli Lilly and Company (LLY) Said on Its Q3 Earnings Call

Eli Lilly (LLY) reported Q3 earnings, highlighting Mounjaro's $1B revenue in China, 53% YoY growth in international incretin business, and 500,000+ Medicare Bridge Program enrollments. Foundayo, its oral obesity medicine, gained traction in the U.S. and international markets. Gross margin rose to 84.4%, while R&D spending increased 23%. Lilly expects continued growth in 2027, with potential U.S. type 2 diabetes launch for Foundayo.

finance.yahoo.com3 min
OCT 30
$LLYMed

BofA Makes Major Call on Eli Lilly Stock

Bank of America raised its price target for Eli Lilly (LLY) to $1,497 from $1,397, citing stronger-than-expected Q3 results and raised 2026 revenue outlook. LLY reported $24.4B revenue and $7.48 EPS, beating estimates. BofA increased revenue and EPS forecasts, noting strong demand for obesity and diabetes drugs.

finance.yahoo.com2 min
OCT 30
$LLYHighAI 9/10

Eli Lilly Stocks Rise 3.4% With Higher Sales but Lower EPS Guidance

Eli Lilly (LLY) raised its annual revenue guidance to $91B-$92B, up from $85B-$87B, but lowered its adjusted earnings guidance to $35-$36 per share. Shares rose 3.41% to $1,420.53 on October 30. Scotiabank increased its price target to $1,605, maintaining an Outperform rating. The changes reflect higher research spending due to acquisitions.

finance.yahoo.com1 min
OCT 30
$LLYMed

SHINE-2 and Closing the Pediatric UC Treatment Gap, With Marla Dubinsky, MD

Eli Lilly's mirikizumab showed positive results in treating pediatric ulcerative colitis in the phase 3 SHINE-2 study, with 41.3% of participants achieving clinical remission at week 12. The drug is not yet approved for pediatric use, but Lilly plans to submit the data to global regulators. Current treatments for pediatric UC are limited, and mirikizumab could address this gap.

hcplive.com3 min